Published in Proc Natl Acad Sci U S A on January 23, 2017
Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol (2017) 0.83
Vasculitis syndromes: Loss of immunoinhibitory checkpoint implicated in GCA. Nat Rev Rheumatol (2017) 0.75
Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol (2017) 0.75
Immune Checkpoint Dysfunction in Medium and Large Vessel Vasculitis. Am J Physiol Heart Circ Physiol (2017) 0.75
Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest (2017) 0.75
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol (2003) 6.07
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity (2004) 4.60
Medium- and large-vessel vasculitis. N Engl J Med (2003) 3.96
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A (2001) 3.32
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature (2015) 3.06
The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol (2008) 2.85
Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol (2012) 2.79
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol (2001) 2.71
TGF-β signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med (2014) 2.07
Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation (2008) 1.91
B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol (2002) 1.90
Th17 and Th1 T-cell responses in giant cell arteritis. Circulation (2010) 1.88
Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med (2004) 1.70
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest (1996) 1.54
NADPH oxidase deficiency underlies dysfunction of aged CD8+ Tregs. J Clin Invest (2016) 1.53
Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med (1994) 1.52
Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol (2013) 1.48
Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum (1997) 1.44
Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol (1996) 1.43
Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol (1999) 1.41
IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest (2001) 1.39
Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum (2011) 1.38
Participation of blood vessel cells in human adaptive immune responses. Trends Immunol (2011) 1.30
IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol (2011) 1.26
Tissue-destructive macrophages in giant cell arteritis. Circ Res (1999) 1.23
Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol (2008) 1.23
Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum (1998) 1.19
Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci (2005) 1.14
Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation (2011) 1.12
Arterial wall injury in giant cell arteritis. Arthritis Rheum (1999) 1.04
The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J Exp Med (2016) 0.90
CD4+ and CD8+ T cell expansions using selected TCR V and J gene segments at the onset of giant cell arteritis. Arthritis Rheum (1994) 0.90
Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford) (2008) 0.88
Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. Rheumatology (Oxford) (2012) 0.86
Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol (2014) 0.85
Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatology (Oxford) (2015) 0.84
Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. Eur J Immunol (2015) 0.81
Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis (2007) 0.79
Biopsy-negative giant cell arteritis: Does anti-CD83 immunohistochemistry advance the diagnosis? Eur J Intern Med (2007) 0.77